Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C
- PMID: 35914252
- DOI: 10.7326/J22-0060
Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C
Abstract
Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022;377:e069066. 35508320.
Comment on
-
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.BMJ. 2022 May 4;377:e069066. doi: 10.1136/bmj-2021-069066. BMJ. 2022. PMID: 35508320
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous